A case report of rhabdomyolysis caused by the use of roxadustat in the
treatment of caused by renal anemia
Abstract
More than 1.2 million people died from chronic kidney damage (CKD)
globally, in 2017. Anemia is a common complication of CKD. Roxadustat is
an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and regulates iron metabolism. Roxadustat is
often used to treat anemia caused by renal diseases. Its adverse effects
include high blood pressure, myocardial infarction, heart failure, high
potassium, and dizziness; however, there are no reports about
rhabdomyolysis associated with roxadustat. One of our patients developed
rhabdomyolysis after he was administered roxadustat to treat anemia
caused by chronic renal failure. Physicians should be alert about the
occurrence of rhabdomyolysis when roxadustat is used.